Neoplasms
Conditions
Brief summary
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
Interventions
BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
Sponsors
Boehringer Ingelheim
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
There are 2 Steps in the screening process: Step 1 Inclusion criteria for pre-screening: 1. Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories: Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers 2. Measurable disease by RECIST criteria. 3. Willingness and ability to give written informed consents consistent with ICHGCP guidelines. 4. Life expectancy of at least three (3) months. 5. Eastern Cooperative Oncology Group performance score 0, 1 or 2. 6. Age \>18 years. Step 2 Inclusion criteria for enrollment: Patients who have tested positive for FISH and are considered candidate for this trial must meet all of the following inclusion criteria: 1. Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories: Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers 2. Documented failure to respond or progression of underlying cancer after at least one line of prior chemotherapy. 3. EGFR and/or HER2 gene amplification by FISH testing or patients with tumors that harbor known activating EGFR mutations. 4. Measurable disease by RECIST criteria. 5. Willingness and ability to give written informed consents consistent with ICH-GCP guidelines. 6. Life expectancy of at least three (3) months. 7. Eastern Cooperative Oncology Group performance score 0, 1 or 2. 8. Age \>18 years.
Exclusion criteria
1. Prior treatment with gefitinib, erlotinib, lapatinib and/or other EGFR TKIs. 2. Treatment with cytotoxic anti-cancer-therapies or investigational drugs during the last four weeks prior to the first treatment with the trial drug. (a shorter duration may be considered for patients treated with oral, non cytotoxic drugs on an individual basis and upon discussion between the principal investigator and sponsor) 3. Inability to take BIBW 2992 by mouth (BIBW 2992 may not be crushed or administered via Gastrostomy-tube) 4. Chronic diarrhea or other gastrointestinal disorders that may interfere with the absorption of the trial drug. 5. History of other malignancies unless free of disease for at least 3 years (except for appropriately treated superficial non-melanoma skin cancer and surgically cured cervical cancer in situ). 6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization. 7. Resting left ventricular ejection fraction \<50% OR below the institution's lower limit of normal (if the institutions lower limit is above 50%), measured by MUGA scan or echocardiogram. 8. Active infectious disease 9. Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with participation in this trial. 10. Active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal brain MRI scan at screening and be at least three months post-radiation or surgery for brain metastasis. 11. Absolute Neutrophil Count (ANC) less than 1,000/mm3. 12. Platelet count less than 100,000/mm3. 13. Hemoglobin Level less than 9.0 grams/dl. 14. Total Bilirubin greater than 1.5 mg/dl; higher Total Bilirubin values may be acceptable for patients with known Gilbert¿s disease, approval by the PI and sponsor will be necessary. 15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal; or 5 times the upper limit of normal in patients with neoplastic liver involvement. 16. Serum creatinine greater than 1.5 x upper limit of normal for the institution. 17. Patients who are sexually active and unwilling to use simultaneously two medically acceptable method of contraception, one of which being a barrier type method such as condom. 18. Pregnancy or breast-feeding. 19. Patients unable to comply with the protocol 20. Active alcohol and/or substance abuse. 21. Continuation of therapy-related toxicities from prior anti cancer therapies, prior surgery, of CTCAE Grade \>=2 at the time of the first administration of the trial drug. 22. Patients with known pre-existing interstitial lung disease. 23. Requirement for treatment with any of the prohibited concomitant medications: additional experimental anti-cancer treatment and/or standard chemotherapy, immunotherapy, hormone treatment or radiotherapy; P-gp inhibitors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Objective Response (OR) | Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks thereafter | OR is defined as the percentage of patients with complete response (CR) or partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Objective Response (OR) | Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock | The time to OR was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST 1.0 criteria. |
| Duration of OR | Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock. | Duration of OR was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death was objectively documented. |
| Progression-free Survival (PFS) | Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock. | PFS was defined as the time from the start of treatment to the occurrence of disease progression or death, whichever came first. Disease progression was assessed according to RECIST 1.0 criteria as well as by the investigators assessment, progression date recorded from post trial follow up or start of new anticancer treatment. |
| Percentage of Participants With Clinical Benefit (CB) | Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock | CB was defined as CR, PR or stable disease (SD) and was assessed according to RECIST 1.0 criteria. |
| Maximum CTCAE Grade | First administration of trial medication until 28 days after last administration of trial medication | Patients with AEs by maximum Common Terminology Criteria for Adverse Events (CTCAE) grade |
| Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) for Patients on 50mg on Day 15 | Day 15 | Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15 for patients on 50mg on day 15. |
| Number of Patients With Diarrhea or Rash | First administration of trial medication until 28 days after last administration of trial medication | Number of Patients with Diarrhea or Rash |
| Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation | First administration of trial medication until 28 days after last administration of trial medication | Patients with adverse events (AEs) resulting in dose reduction or treatment discontinuation |
Countries
Taiwan, United States
Participant flow
Recruitment details
The trial was terminated earlier than planned because of a high screen-failure rate and recruitment challenges that prevented full accrual; no safety or efficacy findings influenced this decision.
Participants by arm
| Arm | Count |
|---|---|
| Afatinib 50mg Patients with genetically pre-screened cancers with EGFR and/or HER2 gene amplification or EGFR activating mutations treated with afatinib 50mg once daily. | 20 |
| Total | 20 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Drug reducing Toxity | 2 |
| Overall Study | Other Adverse Event | 1 |
| Overall Study | Other Reasons | 1 |
| Overall Study | Progressive disease | 15 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Afatinib 50mg |
|---|---|
| Age, Continuous | 64.1 years STANDARD_DEVIATION 6.2 |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 20 / 20 |
| serious Total, serious adverse events | 6 / 20 |
Outcome results
Primary
Percentage of Participants With Objective Response (OR)
OR is defined as the percentage of patients with complete response (CR) or partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).
Time frame: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks thereafter
Population: Treated Set (TS). TS consisted of all patients who received at least one dose of trial medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Afatinib 50mg | Percentage of Participants With Objective Response (OR) | 5.0 percentage of patients |
Secondary
Duration of OR
Duration of OR was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death was objectively documented.
Time frame: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
Population: Trial terminated early, therefore no data summaries produced for duration of OR.
Secondary
Maximum CTCAE Grade
Patients with AEs by maximum Common Terminology Criteria for Adverse Events (CTCAE) grade
Time frame: First administration of trial medication until 28 days after last administration of trial medication
Population: TS
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Afatinib 50mg | Maximum CTCAE Grade | Grade 1 | 2 Participants |
| Afatinib 50mg | Maximum CTCAE Grade | Grade 2 | 5 Participants |
| Afatinib 50mg | Maximum CTCAE Grade | Grade 3 | 10 Participants |
| Afatinib 50mg | Maximum CTCAE Grade | Grade 4 | 0 Participants |
| Afatinib 50mg | Maximum CTCAE Grade | Grade 5 | 3 Participants |
Secondary
Number of Patients With Diarrhea or Rash
Number of Patients with Diarrhea or Rash
Time frame: First administration of trial medication until 28 days after last administration of trial medication
Population: TS
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Afatinib 50mg | Number of Patients With Diarrhea or Rash | AE : Diarrhea | 18 Participants |
| Afatinib 50mg | Number of Patients With Diarrhea or Rash | AE : Rash | 12 Participants |
Secondary
Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation
Patients with adverse events (AEs) resulting in dose reduction or treatment discontinuation
Time frame: First administration of trial medication until 28 days after last administration of trial medication
Population: TS
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Afatinib 50mg | Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation | With AE leading to drug discontinuation | 5 Participants |
| Afatinib 50mg | Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation | With AE leading to dose reduction | 1 Participants |
| Afatinib 50mg | Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation | With Treatment held or paused due to AE | 8 Participants |
Secondary
Percentage of Participants With Clinical Benefit (CB)
CB was defined as CR, PR or stable disease (SD) and was assessed according to RECIST 1.0 criteria.
Time frame: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
Population: TS.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Afatinib 50mg | Percentage of Participants With Clinical Benefit (CB) | With CB | 45.0 percentage of patients |
| Afatinib 50mg | Percentage of Participants With Clinical Benefit (CB) | Without CB | 55.0 percentage of patients |
Secondary
Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) for Patients on 50mg on Day 15
Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15 for patients on 50mg on day 15.
Time frame: Day 15
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Afatinib 50mg | Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) for Patients on 50mg on Day 15 | 33.2 ng/mL | Geometric Coefficient of Variation 80 |
Secondary
Progression-free Survival (PFS)
PFS was defined as the time from the start of treatment to the occurrence of disease progression or death, whichever came first. Disease progression was assessed according to RECIST 1.0 criteria as well as by the investigators assessment, progression date recorded from post trial follow up or start of new anticancer treatment.
Time frame: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
Population: Trial terminated early, therefore no data summaries produced for PFS.
Secondary
Time to Objective Response (OR)
The time to OR was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST 1.0 criteria.
Time frame: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
Population: Trial terminated early, therefore no data summaries produced for time to OR.